Another week in the books. I do admit that Brilacidin got me really excited last year - we started up the trial, moved steadily through enrolling patients, completed the trials and got top-line results. We even met with the FDA about the results and they simply asked for "more data".
Now, 4 months after that meeting, we've had no progress on that front. Sure, Kevetrin has completed another cohort, we've got some IND studies in the works, and even a new round of financing, but Brilacidin is really what is going to move the needle in the next year or so. A partnership, revenue stream and likely even uplisting are all tied to Brilacidin advancing into a Phase 3. It does seem like it's inevitable that it will start, but the waiting is really, really hard.
I'm long, and I've been here for a while, and I don't plan on going anywhere soon. But it doesn't make the wait any easier, and I can see why the natives are growing restless. Hopefully the comprehensive update and/or the ECCMID conference will give us information on things moving again.
Market Data 
Markets 
AI
